What is cognoas first product? The company’s AI technology platform will enable Cognoa's product pipeline to address additional unmet needs including ADHD and anxiety. Cognoa plans to commercialize its first product, the first digital autism diagnosis aid, under the name Canvas Dx™ and expects to begin making Canvas Dx™ available in the U.S. later in 2021.What is cognoa doing for behavioral health? We are developing digital diagnostics and therapeutics with the goal of enabling earlier and more equitable care for behavioral health conditions. We’re excited to announce that the FDA has granted marketing authorization for Cognoa’s autism diagnosis aid.Is cognoa approved by the fda for autism diagnosis aid? We’re excited to announce that the FDA has granted marketing authorization for Cognoa’s autism diagnosis aid. Cognoa is committed to developing products for earlier diagnosis and treatment, with the goal of improving lifelong outcomes for children and families.Why choose cognoa for your lead product? Cognoa is committed to developing products for earlier diagnosis and treatment, with the goal of improving lifelong outcomes for children and families. Our lead products aim to enable earlier and more equitable treatment of behavioral health conditions.
About Cognoa OUR MISSION Cognoa is a pediatric behavioral health company developing diagnostic and therapeutic solutions with the goals of enabling equitable access to care and improving the lives and outcomes of children and families living with behavioral health conditions, starting with autism. 1 in 0 *1 in 5 children in the U.S. is affected by a diagnosable behavioral ...